PRoMOTE Follow-up Observational Study
PRoMOTE FU
Patient Risk Triage in ICD Remote Follow-up Observational Study (PRoMOTE FU)
1 other identifier
observational
287
0 countries
N/A
Brief Summary
The purpose of the study is:
- To evaluate the Heart Failure Risk Status (HFRS) feature performance.
- To establish the feasibility of remote follow-up in which patient risk triaging is performed by nurse-led review of HFRS feature as supplemental information.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2013
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2014
CompletedFirst Submitted
Initial submission to the registry
January 11, 2016
CompletedFirst Posted
Study publicly available on registry
January 4, 2017
CompletedJuly 2, 2025
June 1, 2025
1.2 years
January 11, 2016
June 30, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Clinical Data collected through the phone call to the patients during the 6 months of study duration will be correlated to the HF risk classification provided by the HFRS feature on each transmission.
6 months
Interventions
Eligibility Criteria
Study population will include patients of both sexes included in the Medtronic CareLink® Network and implanted with a Medtronic wireless implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy device with defibrillation capabilities device (CRT-D) at Hospital Araba (former Hospital Txagorritxu). There are approximately 223 ICD and CRT-D patients included in the CareLink® Network at this site, and average number of transmissions per month is \~80, so it is expected that 480 transmissions are received during the study duration. From this population, less than 10% are implanted with a device without Optivol® feature. For these patients we will not have HFRS data.
You may qualify if:
- Patients that meet all of following criteria could be included in the study:
- Implant of a commercially available Medtronic CRTD or ICD device with or without the Optivol Fluid Status Monitoring feature.
- Local consent available for CL network as well as general local consent available for the use of data in observational studies signed and informative sheet delivered.
You may not qualify if:
- Patients under the age of 18 years.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 11, 2016
First Posted
January 4, 2017
Study Start
June 1, 2013
Primary Completion
August 1, 2014
Study Completion
August 1, 2014
Last Updated
July 2, 2025
Record last verified: 2025-06